Phenotypes associated with this allele

• Allele Symbol: Tcf3^{tm1(TCF3/HLF)Homy}
• Allele Name: targeted mutation 1, Hiroaki Honda
• Allele ID: MGI:4458115
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Tcf3^tm1(TCF3/HLF)Homy/Tcf3^+	involves: 129P2/OlaHsd * C57BL/6	MGI:4458208
cn2	Tcf3^tm1(TCF3/HLF)Homy/Tcf3^+ Tg(Mx1-cre)1Cgn/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:4458207
cn3	Tcf3^tm1(TCF3/HLF)Homy/Tcf3^+ Tg(Emu-Zfp521)1Homy/0 Tg(Mx1-cre)1Cgn/0	involves: 129P2/OlaHsd * C57BL/6 * CBA	MGI:4458210

Genotype
MGI:4458208

ht1

• Allelic Composition: Tcf3^{tm1(TCF3/HLF)Homy}/Tcf3⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

mortality/aging ( J:160392 )

N • mice have a normal lifespan

hematopoietic system

hematopoietic system phenotype ( J:160392 )

N • mice exhibit no abnormalities in peripheral blood

Genotype
MGI:4458207

cn2

• Allelic Composition: Tcf3^{tm1(TCF3/HLF)Homy}/Tcf3⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

mortality/aging

mortality/aging ( J:160392 )

N • pIpC-treated mice have a normal lifespan

increased susceptibility to induced morbidity/mortality ( J:160392 )

• mice treated with pIpC and Moloney murine leukemia virus (MMLV) exhibit increased morbidity and mortality with all mice dying by 6 months of age unlike with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

hematopoietic system

hematopoietic system phenotype ( J:160392 )

N • pIpC-treated mice exhibit no abnormalities in peripheral blood

abnormal B cell differentiation ( J:160392 )

• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

increased B cell number ( J:160392 )

• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

neoplasm

increased incidence of induced tumors ( J:160392 )

• mice treated with pIpC and Moloney murine leukemia virus (MMLV) exhibit increased morbidity and mortality with all mice dying by 6 months of age unlike with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

• mice treated with pIpC and MMLV develop only acute B-progenitor and lineage marker negative leukemias as early as 2.6 months compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes that develop T cell leukemias at 4 to 6 months

homeostasis/metabolism

abnormal thrombosis ( J:160392 )

• pIpC-treated and Moloney murine leukemia virus (MMLV)-exposed mice develop microthrombi

immune system

abnormal B cell differentiation ( J:160392 )

• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

increased B cell number ( J:160392 )

• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

Genotype
MGI:4458210

cn3

• Allelic Composition: Tcf3^{tm1(TCF3/HLF)Homy}/Tcf3⁺; Tg(Emu-Zfp521)1Homy/0; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

mortality/aging

premature death ( J:160392 )

• within 6 months, pIpC-treated mice die of leukemia

neoplasm

increased leukemia incidence ( J:160392 )

• pIpC-treated mice develop acute B-lineage leukemia by 6 months of age unlike control mice